Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is one of the 10 Best Penny Stocks to Buy for the Next 5 Years. On August 5, Needham reiterated its Buy rating on Recursion Pharmaceuticals, Inc.

What if you could create your very own personal AI assistant—one that could research, analyze, and even interact with tools—all from scratch? It might sound like a task reserved for seasoned ...

Recursion Pharmaceuticals reported significant growth in sales and revenue for Q2 and the first half of 2025 but also experienced widening net losses. The release of their Boltz-2 model underscored a ...

Taylor Stanberry won the 2025 Florida Python Challenge, removing 60 invasive Burmese pythons. The first-time participant earned $10,000 for her efforts during the 10-day competition. Stanberry, along ...

Have you ever wished you could create stunning visuals without spending hours learning complicated design software? Imagine describing your ideal image—whether it’s a vibrant anime-inspired ...

If you would like to learn more about the IAEA’s work, sign up for our weekly updates containing our most important news, multimedia and more. Peter Lee, IAEA Department of Nuclear Sciences and ...

Star Trek: Strange New Worlds has many out-of-this-world elements, as a show set in the future about aliens and cosmic anomalies. However, many Trekkies agree that the perfectly coifed hair of one ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

Recursion shares jumped over 18% after launching Boltz-2, a breakthrough AI model with MIT that predicts molecular binding The open-source model significantly accelerates drug discovery, making ...